Assertio Therapeutics looks to get out of Glumetza antitrust case
MLex Summary: Assertio Therapeutics others filed a motion to dismiss end-payor plaintiffs and direct purchaser plaintiffs’ claims alleging that it engaged in an illegal pay-for-delay agreement concerning the diabetes drug Glumetza, resulting...To view the full article, register now.
Already a subscriber? Click here to view full article